Ameriprise Financial Inc. Has $6.72 Million Holdings in Xencor, Inc. (NASDAQ:XNCR)

Ameriprise Financial Inc. grew its stake in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 72.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 292,576 shares of the biopharmaceutical company's stock after purchasing an additional 122,870 shares during the quarter. Ameriprise Financial Inc. owned 0.42% of Xencor worth $6,723,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Sterling Capital Management LLC lifted its stake in shares of Xencor by 732.4% in the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 1,040 shares in the last quarter. KBC Group NV lifted its stake in shares of Xencor by 26.0% in the fourth quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company's stock worth $90,000 after acquiring an additional 813 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in shares of Xencor by 49.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company's stock worth $93,000 after acquiring an additional 1,337 shares in the last quarter. Summit Investment Advisors Inc. lifted its stake in shares of Xencor by 22.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,045 shares of the biopharmaceutical company's stock worth $162,000 after acquiring an additional 1,282 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in shares of Xencor by 132.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,865 shares of the biopharmaceutical company's stock worth $181,000 after acquiring an additional 4,482 shares in the last quarter.

Xencor Stock Performance

Shares of Xencor stock traded up $0.02 on Wednesday, reaching $7.77. 49,229 shares of the company were exchanged, compared to its average volume of 773,374. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. The company's 50-day moving average is $9.45 and its two-hundred day moving average is $16.48. The firm has a market cap of $553.00 million, a price-to-earnings ratio of -2.43 and a beta of 0.99. Xencor, Inc. has a 1-year low of $7.16 and a 1-year high of $27.24.

Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.06). The company had revenue of $32.73 million for the quarter, compared to the consensus estimate of $23.44 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The business's revenue was up 104.6% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.11) earnings per share. As a group, research analysts expect that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Wells Fargo & Company cut their price target on Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. Wall Street Zen cut Xencor from a "hold" rating to a "sell" rating in a research note on Friday, March 14th. Barclays cut their price objective on Xencor from $22.00 to $6.00 and set an "underweight" rating on the stock in a research note on Thursday, May 8th. William Blair assumed coverage on Xencor in a research note on Monday, April 21st. They set an "outperform" rating on the stock. Finally, Wedbush restated an "outperform" rating and set a $31.00 price objective on shares of Xencor in a research note on Wednesday, April 30th. Two research analysts have rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Xencor has an average rating of "Moderate Buy" and a consensus target price of $29.50.

Insider Activity at Xencor

In other Xencor news, EVP Nancy Valente sold 4,616 shares of the business's stock in a transaction dated Friday, May 2nd. The stock was sold at an average price of $11.03, for a total value of $50,914.48. Following the completion of the sale, the executive vice president now owns 49,169 shares of the company's stock, valued at $542,334.07. The trade was a 8.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 4.76% of the company's stock.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.